Ifosfamide-induced Nephrotoxicity in Children: Critical Review of Predictive Risk Factors
Authors:
Open Access
- 1 June 1998
- journal article
- review article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 101 (6) , e8
Abstract
Ifosfamide is widely used in the treatment of pediatric solid tumors. Its main adverse effects are various forms of renal tubular and glomerular damage. Many risk factors have been proposed to play a role in the development and severity of nephrotoxicity in children receiving ifosfamide, among which are 1) patient9s age, 2) cumulative ifosfamide dose, 3) concurrent administration of cis or carboplatinum, 4) unilateral nephrectomy, and 5) method of ifosfamide administration. However, presently there is no consensus regarding the weight of each one of them. Therefore, we critically reviewed the major studies that have evaluated the different risk factors in an attempt to determine the relative importance of each. Cumulative ifosfamide doses of ≥60 g/m2 appears to be the most consistent independent predictor for both the development and the severity of nephrotoxicity, whereas a younger age (2should be considered carefully, especially in children <5 years of age.Keywords
This publication has 14 references indexed in Scilit:
- Progressive glomerular toxicity of ifosfamide in childrenMedical and Pediatric Oncology, 1996
- Risk factors for ifosfamide nephrotoxicity in childrenThe Lancet, 1996
- Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.Journal of Clinical Oncology, 1994
- Renal function in children and adolescents following 72 g/m2 of ifosfamideCancer Chemotherapy and Pharmacology, 1994
- Renal function abnormalities after ifosfamide treatment in childrenActa Paediatrica, 1993
- Iphosphamide-induced nephrotoxicity in childrenPediatric Nephrology, 1992
- Ifosfamide in pediatric oncologyAnti-Cancer Drugs, 1991
- Ifosfamide-induced renal tubular defectsCancer, 1989
- Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.Journal of Clinical Oncology, 1987
- Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)European Journal of Cancer and Clinical Oncology, 1982